We offer transformational solutions for unmet needs in life sciences and pharmaceuticals. Starpharma has adopted a well-defined approach to partnering that aims to deliver solutions and add value to partners, covering a wide range of products and therapeutic areas using our proprietary dendrimer technology.
Starpharma has partnered with leading pharmaceutical companies to commercialise a range of products developed using its proprietary dendrimer technology.
Further partnering and licensing opportunities are available.
Partners can access Starpharma’s novel DEP® drug delivery platform under a research collaboration or licence, to create significant leverage and optionality. Starpharma’s DEP® platform can enhance the commercial and therapeutic value of a wide range of drugs, making it a highly valuable partnering technology.
Our Dendrimer Technology offers multiple collaboration and licensing opportunities for therapy approaches in many areas including oncology chemotherapeutics, ImmunoOncology, non-oncology molecules, ADCs, radiopharmaceuticals, and beyond.
Starpharma is actively seeking partners for its DEP® drug delivery platform, and to combine partners’ molecule/compounds of interest with DEP® therapeutics to develop novel proprietary therapies.
Contact our business development team to discuss DEP® partnering opportunities.
Sales and Distribution partners
Starpharma is seeking to expand the sales and distribution of its VivaGel® and VIRALEZE™ products in countries where these products are approved and is looking for partners with strong distribution and marketing capabilities.
If you are interested in licensing or obtaining distribution rights to our VivaGel® and/or VIRALEZE™ products, contact our business development team.
Partner with us
Contact our business development team to explore partnership opportunities with Starpharma.